hydroxyurea has been researched along with adenosine monophosphate in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
David, JC; Marquet, J; Zittoun, J | 1 |
Feng, W; Peng, J | 1 |
Buono, A; De Blasio, G; Ielasi, A; Loffi, M; Tespili, M | 1 |
Anderson, EJ; Edara, VV; Grubbs, G; Khurana, S; Lapp, SA; Patel, PA; Pauly, MG; Piantadosi, A; Rostad, CA; Sabnis, HS; Stokes, CL; Suthar, MS | 1 |
4 other study(ies) available for hydroxyurea and adenosine monophosphate
Article | Year |
---|---|
Mechanism of inhibition of DNA ligase in Ara-C treated cells.
Topics: Adenosine Monophosphate; Arabinofuranosylcytosine Triphosphate; Cytarabine; DNA Ligases; Humans; Hydroxyurea; Leukemia, Myeloid; Tumor Cells, Cultured | 1991 |
Incision of damaged DNA in the presence of an impaired Smc5/6 complex imperils genome stability.
Topics: Adenosine Monophosphate; Cell Cycle; Cell Cycle Proteins; DNA Damage; DNA Mismatch Repair; DNA Repair; DNA Replication; DNA, Single-Stranded; Fungal Proteins; Genome, Fungal; Genomic Instability; Hydroxyurea; Multiprotein Complexes; Mutation; Protein Binding; Ribonuclease H; Stress, Physiological | 2016 |
Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.
Topics: Adenosine Monophosphate; Adult; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug-Eluting Stents; Humans; Hydroxyurea; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; ST Elevation Myocardial Infarction; Thrombocythemia, Essential; Treatment Outcome | 2020 |
Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
Topics: Adenosine Monophosphate; Adolescent; Alanine; Antimalarials; Antineoplastic Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disease Management; Humans; Hydroxychloroquine; Hydroxyurea; Leukemia, Myeloid, Acute; Male; SARS-CoV-2; Young Adult | 2021 |